- Conditions
- Drug Abuse
- Interventions
- Brief advice, Brief Intervention plus Booster, Brief Intervention
- Behavioral
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 583
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
- Interventions
- DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine, Venetoclax, GM-CSF
- Biological · Drug
- Lead sponsor
- David Avigan
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Covid-19, Coronavirus Infection, Coronavirus
- Interventions
- COVID-19 Serology, Health Care Worker Survey
- Other · Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
- Interventions
- Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy
- Radiation · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Allergic Contact Dermatitis
- Interventions
- Patch tests
- Other
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Dietary Supplement · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Duarte, California • Irvine, California
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- flow cytometry, immunoenzyme technique, laboratory biomarker analysis
- Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Breast Carcinoma, Invasive Breast Carcinoma
- Interventions
- Biopsy, Biospecimen Collection, Radiation Therapy
- Procedure · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma, Precancerous Condition
- Interventions
- vandetanib, placebo, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, pharmacological study
- Drug · Other · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Interventions
- decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride, sargramostim, incomplete Freund's adjuvant, immunohistochemistry staining method, liquid chromatography, mass spectrometry, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, DNA methylation analysis, enzyme-linked immunosorbent assay
- Drug · Biological · Other + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
- Interventions
- E7 TCR-T cells, Aldesleukin
- Biological · Drug
- Lead sponsor
- Christian Hinrichs
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • New Brunswick, New Jersey
- Conditions
- Pancreatic Cancer
- Interventions
- erlotinib hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Stage IV Pancreatic Cancer
- Interventions
- Gemcitabine, nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin, mFOLFIRI
- Drug · Genetic
- Lead sponsor
- Pancreatic Cancer Research Team
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Burbank, California • Minneapolis, Minnesota + 2 more
- Conditions
- Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Interventions
- immunologic technique, laboratory biomarker analysis, mass spectrometry
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Interventions
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Questionnaire Administration
- Biological · Drug · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2035
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Contact Dermatitis
- Interventions
- Patch Test
- Biological
- Lead sponsor
- Allerderm
- Industry
- Eligibility
- 6 Years to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Louisville, Kentucky
- Conditions
- Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney Transplantation
- Interventions
- Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)
- Procedure · Drug
- Lead sponsor
- Tatsuo Kawai, MD, PhD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- panitumumab, paclitaxel, carboplatin, laboratory biomarker analysis, immunohistochemistry staining method
- Biological · Drug · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana • Winston-Salem, North Carolina
- Conditions
- Pancreatic Cancer
- Interventions
- bevacizumab, fluorouracil, gemcitabine hydrochloride, oxaliplatin, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, endoscopic biopsy, laparoscopy, radiation therapy
- Biological · Drug · Other + 2 more
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Severe Combined Immunodeficiency
- Interventions
- Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 3 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
- Interventions
- Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 (SP263 or SP142) assay
- Biological · Drug · Device
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma, Pancreatic Ductal Adenocarcinoma
- Interventions
- Blood collection for research (next-generation sequencing [NGS]), Blood collection for research (HLA typing)
- Procedure
- Lead sponsor
- Gritstone bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • New York, New York • Columbus, Ohio + 2 more
- Conditions
- Kaposi's Sarcoma
- Interventions
- VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
- Drug · Genetic · Other + 1 more
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 8
- States / cities
- La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 4 more
- Conditions
- Immunity
- Interventions
- Protocatechuic Acid or PCA, Placebo
- Dietary Supplement
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 50 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania